Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Listing of Nyrada Inc. spin-off on ASX (ASX:NOX)

Noxopharm (ASX: NOX) announces the listing today on the ASX (ASX: NYR) of its spin-off company, Nyrada Inc (Nyrada). The IPO Offer was fully subscribed, with A$8.5M being raised. For mor...read more

Noxopharm announces DARRT-1 Clinical Data Webinar (ASX:NOX)

Noxopharm (NOX:ASX) releases a webinar containing further details on its DARRT-1 study clinical data read-out, along with a commentary from prominent Australian medical oncologist, Professor Paul de...read more

Noxopharm announces Nyrada IPO Offer Fully Subscribed (ASX:NOX)

The Boards of both Noxopharm Ltd (ASX:NOX) and Nyrada Inc (‘Nyrada’) are pleased to announce that commitments for the Maximum Subscription of $8,500,000 for the Nyrada Initial Public Off...read more

Noxopharm announces lodgement of supplementary prospectus (ASX:NOX)

Sydney, 9 December 2019: Noxopharm Limited (ASX:NOX) advises that its subsidiary, Nyrada Inc. (Nyrada), has today lodged a supplementary prospectus (Supplementary Prospectus) with ASIC. The suppl...read more

Nyrada Inc. – Initial Public Offering Opens (ASX:NOX)

Noxopharm (ASX:NOX) announces the opening of the offer period under the Prospectus relating to the Initial Public Offering (IPO) of Nyrada Inc. (‘Nyrada’) (ARBN 625 401 818). Nyrada also...read more

Noxopharm announces AU$2.4m increase to funding agreement (ASX:NOX)

KEY HIGHLIGHTS AU$2,400,000 extension of existing convertible security Agreement Short-term funding earmarked for pharmacokinetic study SYDNEY, December 3rd, 2019: Noxopharm Ltd (ASX:NOX) i...read more

Noxopharm (ASX:NOX) positive DARRT-1 data in late-stage prostate cancer (ASX:NOX)

Positive DARRT-1 data in late-stage prostate cancer Clinical responses point to the NOX66 DARRT treatment regimen as a potentially major new treatment option for men with late-stage prostate canc...read more

Noxopharm Limited (ASX:NOX) - trading halt (ASX:NOX)

The securities of Noxopharm Limited ('NOX') will be placed in trading halt at the request of NOX, pending it releasing an announcement. Unless ASX decides otherwise, the securities will rema...read more

Noxopharm, Lodgement of Nyrada Inc Prospectus - Initial Public Offering (ASX:NOX)

Noxopharm Limited (ASX: NOX) advises that its subsidiary, Nyrada Inc, has today lodged with ASIC a prospectus to raise by issue of Chess Depositary Interests (CDIs) between AU$7 million and AU$8.5 m...read more

Noxopharm, Constitution (ASX:NOX)

The name of the Company upon the adoption of this Constitution is Noxopharm Limited. The Company is a public company limited by shares. The replaceable rules contained in the Corporations Act do not...read more

Noxopharm, Results of Meeting (ASX:NOX)

A summary of valid and eligible proxies received for the above meeting was as follows... For more information, download the attached PDF.

Noxopharm, Noxopharm 2019 AGM Corporate Presentations (ASX:NOX)

Noxopharm (ASX: NOX) is pleased to provide shareholders and the market generally the corporate presentations for today’s Annual General Meeting (AGM). Following voting formalities, three prese...read more

Noxopharm, DARRT-1 Interim Data Presented To Conference (ASX:NOX)

Noxopharm (ASX: NOX) confirms the presentation of clinical data concerning NOX66 (Veyonda®) to the 46th Annual Scientific Meeting of the Clinical Oncology Society of Australia (12th-14th Novembe...read more

Noxopharm, LuPIN Data Being Presented To Conference (ASX:NOX)

Noxopharm Announce Appointment of Chief Commercial Officer (ASX:NOX)

Appointment of Chief Commercial Officer Noxopharm has appointed Mr Alexander Hunter as Chief Commercial Officer Mr Hunter is an experienced corporate finance and business executive with ...read more

Viewing: 31 - 45 of 169 Previous | Next